LivaNova PLC (NASDAQ:LIVN) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $99.56.

Several analysts have recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating on shares of LivaNova in a research report on Wednesday. Barclays raised shares of LivaNova to a “strong-buy” rating in a report on Wednesday, October 7th. Stifel Nicolaus set a $85.00 price objective on shares of LivaNova in a research note on Wednesday, August 5th. Wall Street Zen lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Raymond James Financial set a $120.00 target price on shares of LivaNova in a report on Wednesday.

Insiders Place Their Bets

In related news, Director Brooke Story sold 2,300 shares of the business’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the sale, the director directly owned 7,488 shares in the company, valued at approximately $609,672.96. The trade was a 23.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Francesco Bianchi sold 3,500 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the sale, the director directly owned 4,434 shares in the company, valued at $345,896.34. This trade represents a 44.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 7,450 shares of company stock valued at $591,839 over the last ninety days. Corporate insiders own 0.35% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP lifted its holdings in shares of LivaNova by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 1,826,248 shares of the company’s stock worth $116,067,000 after buying an additional 38,320 shares in the last quarter. Janus Henderson Group PLC grew its stake in LivaNova by 1,978.8% during the first quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock valued at $29,961,000 after acquiring an additional 448,703 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in LivaNova during the first quarter valued at approximately $18,327,000. Sei Investments Co. grew its stake in LivaNova by 56.6% during the first quarter. Sei Investments Co. now owns 218,805 shares of the company’s stock valued at $13,907,000 after acquiring an additional 79,088 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in LivaNova by 15.7% during the 1st quarter. Renaissance Technologies LLC now owns 183,000 shares of the company’s stock worth $11,631,000 after acquiring an additional 24,900 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Stock Down 1.3%

LIVN stock opened at $89.99 on Tuesday. The stock has a fifty day moving average of $79.27 and a 200-day moving average of $73.54. LivaNova has a fifty-two week low of $49.73 and a fifty-two week high of $99.38. The company has a market capitalization of $4.96 billion, a price-to-earnings ratio of 30.00 and a beta of 0.91. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.46.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.17. The business had revenue of $393.15 million for the quarter, compared to analysts’ expectations of $381.13 million. LivaNova had a return on equity of 16.10% and a net margin of 13.01%. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business posted $1.11 EPS. As a group, equities research analysts predict that LivaNova will post 3.79 earnings per share for the current year.

About LivaNova

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.